PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company developing a new generation of RNA therapeutics to change the lives of patients with genetic diseases. The company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC has three first-in-class drug candidates in its pipeline across a range of indications, each of which addresses the underlying cause of the disease in question. PYC's operations are focused on discovery, pre-clinical and laboratory work in Australia, and translational, clinical, and regulatory work in the United States. The company's current projects include the development of novel therapies for inherited eye diseases, neurodevelopmental disorders, and kidney diseases.